Lunsumio (mosunetuzumab-axgb) — Medica
B-cell lymphoma (including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, HIV-related B-cell lymphomas, and post-transplant lymphoproliferative disorders) in combination with Polivy
Initial criteria
- Patient is age ≥ 18 years
- Patient has received ≥ one line of systemic therapy
- Medication will be used in combination with Polivy
- Medication is prescribed by or in consultation with an oncologist
Approval duration
1 year